You just read:

Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps

News provided by

Regeneron Pharmaceuticals, Inc.

Oct 16, 2018, 00:59 ET